P. Mazal

发表

Hsp90 stabilizes Cdc25A and counteracts heat shock-mediated Cdc25A degradation and cell-cycle attenuation in pancreatic carcinoma cells.

T. Szekeres, W. Jäger, S. Krieger, 2012, Human molecular genetics.

Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice

M. Mayerhoefer, M. Raderer, B. Kiesewetter, 2022, ESMO open.

Novel mutations of the calcium-sensing receptor impede differential diagnosis of primary hyperparathyroidism and familial hypocalciuric hypercalcemia.

S. Baumgartner-Parzer, C. Scheuba, P. Riss, 2021, Gland surgery.

Papillary thyroid cancer: the value of bilateral diagnostic lymphadenectomy

B. Niederle, C. Scheuba, P. Riss, 2022, Langenbeck's Archives of Surgery.

Management of adrenocortical carcinoma: are we making progress?

A. Haug, M. Raderer, C. Scheuba, 2021, Therapeutic advances in medical oncology.

Treatment patterns and oncological outcome of patients with advanced small intestinal neuroendocrine tumors: real-world data from the Medical University of Vienna

M. Raderer, B. Kiesewetter, P. Mazal, 2022, Therapeutic advances in medical oncology.

PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact

T. Helbich, W. Wadsak, M. Mitterhauser, 2018, Clinical Cancer Research.

Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [177Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer

M. Mitterhauser, J. Tosoian, S. Shariat, 2021, European urology open science.

Pathological features of prostate cancer detected on initial and repeat prostate biopsy: Results of the prospective European prostate cancer detection study

Mesut Remzi, Bob Djavan, A. Zlotta, 2001, The Prostate.

Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1-2 cm in size: a retrospective, Europe-wide, pooled cohort study.

M. Zwahlen, A. Vanoli, I. Brčić, 2023, The Lancet. Oncology.

Does the dose matter? Antiproliferative efficacy and toxicity of everolimus in patients with neuroendocrine tumors – Experiences from a tertiary referral center

M. Raderer, B. Kiesewetter, P. Mazal, 2023, Journal of neuroendocrinology.

Metastatic disease and major adverse cardiovascular events preceding diagnosis are the main determinants of disease-specific survival of pheochromocytoma/paraganglioma: long-term follow-up of 303 patients

P. Mazal, Wolfgang Raber, Raphael Schendl, 2024, Frontiers in endocrinology.